B. Bozkurt{1}, C. Le Roux{2}, S. Wharton{3}, J. Butt{4}, E. Startseva{5}, M. Sumin{5}, S. Marshall{6}, S. Ajaz Hussain{5}, S. Schnaidt{7}, R. Younes{5}, L. Kaplan{8};
{1}Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, {2}University College Dublin School of Medicine, Dublin, IRELAND; Ulster University, Coleraine, United Kingdom, {3}McMaster University, Hamilton, ON; University of Toronto, Toronto, ON, Canada, {4}University of Glasgow, Glasgow, UNITED KINGDOM; Rigshospitalet Copenhagen University Hospital, Copenhagen, DENMARK; Zealand University Hospital, Roskilde, DENMARK and Herlev-Gentofte Hospital, Copenhagen, Denmark, {5}Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, {6}Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, {7}Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, {8}The Obesity and Metabolism Institute, Boston, MA, USA, and Geisel School of Medicine at Dartmouth, Hanover, NH